Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 104

Sort by

Sort Order Select

Journal Articles

Significant pituitary siderosis is common in transfusion-dependent sickle cell disease

Akhila Vadivelan, Eamon K. Doyle, Susan Carson, Christopher Denton, Saranya Veluswamy, Thomas Hofstra, Thomas D. Coates, John Wood

Blood (2024) 144 (13): 1457–1459.

https://doi.org/10.1182/blood.2024025462

Published: 2024

Journal Articles

Management of iron overload: lessons from transfusion-dependent hemoglobinopathies

Thomas D Coates

Blood blood.2023022502.

https://doi.org/10.1182/blood.2023022502

Published: 2024

Includes: Supplemental data

Journal Articles

Introduction to a review series on globin disorders

Thomas D. Coates, Irene Roberts

Blood (2024) 144 (8): 797–798.

https://doi.org/10.1182/blood.2024025678

Published: 2024

Journal Articles

Higher hemoglobin is better in thalassemia

Thomas D. Coates

Blood (2024) 143 (10): 842–844.

https://doi.org/10.1182/blood.2023023294

Published: 2024

Journal Articles

Splenic iron decreases without change in volume or liver parameters during luspatercept therapy

Christopher C. Denton, Sadanand Vodala, Saranya Veluswamy, Thomas C. Hofstra, Thomas D. Coates, John C. Wood

Blood (2023) 142 (22): 1932–1934.

https://doi.org/10.1182/blood.2023021839

Published: 2023

Journal Articles

Myocardial Fibrosis in Sickle Cell Anemia

Katherine Zhuo, Thomas D Coates, John C. Wood, Jon A Detterich

Blood (2023) 142 (Supplement 1): 1127.

https://doi.org/10.1182/blood-2023-179623

Published: 2023

Journal Articles

Nocturnal Autonomic and Vasoconstriction Parameters By Wearable Wrist Photoplethysmography Predict Intensity of Imminent Pain in Subjects with Sickle Cell Disease

Saranya Veluswamy, Payal Shah, Sabrina Sy, Mingjing Chen, Christopher C Denton, Roberta Miyeko Kato, Michael C K Khoo, Thomas D Coates

Blood (2023) 142 (Supplement 1): 3875.

https://doi.org/10.1182/blood-2023-187353

Published: 2023

Journal Articles

Pituitary and Pancreatic Iron Is Present at an Early Age in Transfused Patients with Alpha Thalassemia Major

Christopher C Denton, Susan Mary Carson, Saranya Veluswamy, Thomas Hofstra, John C. Wood, Thomas D Coates

Blood (2023) 142 (Supplement 1): 2477.

https://doi.org/10.1182/blood-2023-185502

Published: 2023

Journal Articles

Efficacy and Safety of Luspatercept in Patients with HbE/β-Thalassemia from the BELIEVE Study: A Subgroup Analysis

Kevin H.M. Kuo, Pranee Sutcharitchan, Ping Chong Bee, Lee Ping Chew, Soo Min Lim, Ai Sim Goh, Sadanand Vodala, Wen-Ling Kuo, Yinzhi Lai, Loyse Felber Medlin, Martina Perin, Luciana Moro Bueno, Thomas D Coates, Vip Viprakasit

Blood (2023) 142 (Supplement 1): 3848.

https://doi.org/10.1182/blood-2023-174082

Published: 2023

Journal Articles

Luspatercept for the Treatment of Anemia in Non-Transfusion-Dependent β-Thalassemia: Final Safety and Efficacy Data from the BEYOND Trial

Ali T Taher, Vip Viprakasit, Antonis Kattamis, Silverio Perrotta, Paolo Ricchi, John B. Porter, Thomas D Coates, Gian Luca Forni, Khaled M. Musallam, Oriana Esposito, Ana Carolina Giuseppi, Wen-Ling Kuo, Marta Reverte, Richard Wei, Luciana Moro Bueno, Maria Domenica Cappellini

Blood (2023) 142 (Supplement 1): 3847.

https://doi.org/10.1182/blood-2023-174097

Published: 2023

Journal Articles

Effect of Luspatercept in β-Thalassemia Patients with β0/β0 Genotype: A Subgroup Analysis of the BELIEVE Study

Sujit Sheth, Olivier Hermine, Ali T. Taher, Kevin H.M. Kuo, John B. Porter, Antonio Piga, Thomas D. Coates, Antonis Kattamis, Loyse Felber Medlin, Wen-Ling Kuo, Natalia Holot, Maria Domenica Domenica Cappellini

Blood (2022) 140 (Supplement 1): 1946–1948.

https://doi.org/10.1182/blood-2022-157511

Published: 2022

Journal Articles

Effect of Luspatercept on Red Blood Cell (RBC) Transfusion Burden, Iron Chelation Therapy (ICT), and Iron Overload in Adults with Transfusion-Dependent β-Thalassemia (TDT) from the BELIEVE Trial: A Long-Term Analysis

Olivier Hermine, Maria Domenica Domenica Cappellini, Ali T. Taher, Thomas D. Coates, Vip Viprakasit, Antonis Kattamis, Jeevan K. Shetty, Marija Bosilkovska Weisskopf, Natalia Holot, Sadanand Vodala, Wen-Ling Kuo, John B. Porter

Blood (2022) 140 (Supplement 1): 8215–8217.

https://doi.org/10.1182/blood-2022-156985

Published: 2022

Journal Articles

Erythroid Response in Patients with Non-Transfusion-Dependent β-Thalassemia Treated with Luspatercept: Long-Term Data from the BEYOND Trial

Ali T. Taher, Vip Viprakasit, Maria Domenica Domenica Cappellini, Antonio Piga, John B. Porter, Thomas D. Coates, Khaled M. Musallam, Gian Luca Forni, Jeevan K. Shetty, Marija Bosilkovska Weisskopf, Richard Wei, Wen-Ling Kuo, Antonis Kattamis

Blood (2022) 140 (Supplement 1): 8210–8212.

https://doi.org/10.1182/blood-2022-157512

Published: 2022

Journal Articles

Early initiation of disease-modifying therapy can impede or prevent diffuse myocardial fibrosis in sickle cell anemia

Omar Niss, Jon Detterich, John C. Wood, Thomas D. Coates, Punam Malik, Michael D. Taylor, Charles T. Quinn

Blood (2022) 140 (11): 1322–1324.

https://doi.org/10.1182/blood.2021015303

Published: 2022

Includes: Supplemental data

Journal Articles

A Phase 2a Study Evaluating the Safety and Pharmacokinetics (PK) of Luspatercept in Pediatric Patients with Transfusion-Dependent β-Thalassemia (TDT)

Vip Viprakasit, Thomas D. Coates, Khaled M. Musallam, Julie Vienne Buerki, Meera Patturajan, Natalia Holot, Yesim Aydinok

Blood (2021) 138 (Supplement 1): 4161.

https://doi.org/10.1182/blood-2021-145698

Published: 2021

Journal Articles

Trial in Progress: A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of the PKR Activator Etavopivat (FT-4202) in Patients with Thalassemia or Sickle Cell Disease

Ashutosh Lal, R. Clark Clark Brown, Thomas D. Coates, Theodosia A. Kalfa, Janet L. Kwiatkowski, Julie Brevard, Von Potter, Ken W. Wood, Sujit Sheth

Blood (2021) 138 (Supplement 1): 4162.

https://doi.org/10.1182/blood-2021-145752

Published: 2021

Journal Articles

Luspatercept Improves Quality of Life and Reduces Red Blood Cell Transfusion Burden in Patients with Non-Transfusion-Dependent β-Thalassemia in the BEYOND Trial

Antonis Kattamis, Vip Viprakasit, Maria Domenica Cappellini, Ersi Voskaridou, Antonio Piga, John B. Porter, Thomas D. Coates, Gian Luca Forni, Jeevan K. Shetty, Dimana Miteva, Oriana Esposito, Wen-Ling Kuo, Shien Guo, Christopher Pelligra, Jennifer Lord-Bessen, Aylin Yucel, Ali T. Taher

Blood (2021) 138 (Supplement 1): 3081.

https://doi.org/10.1182/blood-2021-148535

Published: 2021

Journal Articles

Loss of Alpha Globin Genes in Human Subjects Is Associated with Improved Nitric Oxide-Mediated Vascular Perfusion

Christopher C Denton, MD, Payal Shah, MS, Silvie Suriany, MS, Honglei Liu, MS, Wanwara Thuptimdang, MS, John Sunwoo, PhD, Patjanaporn Chalacheva, PhD, Saranya Veluswamy, MD, Roberta Miyeko Kato, MD, John C Wood, MD PhD, Jon A Detterich, MD, Michael C.K. Khoo, PhD, Thomas D. Coates, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-136745

Published: 2020

Journal Articles

Sustained Reductions in Red Blood Cell (RBC) Transfusion Burden and Events in β-Thalassemia with Luspatercept: Longitudinal Results of the Believe Trial

Ali T. Taher, Vip Viprakasit, Olivier Hermine, John B. Porter, MA, MD, FRCP, FRCPath, Antonio Piga, MD, Kevin H.M. Kuo, MDMSc,FRCPC, Thomas D. Coates, MD, Ersi Voskaridou, Abderrahim Khelif, Antonis Kattamis, Jeevan K. Shetty, George Zhang, Yu (Olivia) Tian, Dimana Miteva, Tatiana Zinger, Derek Tang, Jay T. Backstrom, Maria Domenica Cappellini

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-140310

Published: 2020

Journal Articles

Longitudinal Effect of Luspatercept Treatment on Iron Overload and Iron Chelation Therapy (ICT) in Adult Patients (Pts) with β-Thalassemia in the Believe Trial

Olivier Hermine, Maria Domenica Cappellini, Ali T. Taher, Thomas D. Coates, MD, Vip Viprakasit, Ersi Voskaridou, Ashutosh Lal, MD, Hong Keng Liew, Silverio Perrotta, Abderrahim Khelif, Antonis Kattamis, Jeevan K. Shetty, George Zhang, Yu (Olivia) Tian, Dimana Miteva, Tatiana Zinger, Derek Tang, Jay T. Backstrom, John B. Porter, MA, MD, FRCP, FRCPath

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-136517

Published: 2020

NARROW

Significant pituitary siderosis is common in transfusion-dependent sickle cell disease

Management of iron overload: lessons from transfusion-dependent hemoglobinopathies

Introduction to a review series on globin disorders

Higher hemoglobin is better in thalassemia

Splenic iron decreases without change in volume or liver parameters during luspatercept therapy

Myocardial Fibrosis in Sickle Cell Anemia

Nocturnal Autonomic and Vasoconstriction Parameters By Wearable Wrist Photoplethysmography Predict Intensity of Imminent Pain in Subjects with Sickle Cell Disease

Pituitary and Pancreatic Iron Is Present at an Early Age in Transfused Patients with Alpha Thalassemia Major

Efficacy and Safety of Luspatercept in Patients with HbE/β-Thalassemia from the BELIEVE Study: A Subgroup Analysis

Luspatercept for the Treatment of Anemia in Non-Transfusion-Dependent β-Thalassemia: Final Safety and Efficacy Data from the BEYOND Trial

Effect of Luspatercept in β-Thalassemia Patients with β0/β0 Genotype: A Subgroup Analysis of the BELIEVE Study

Effect of Luspatercept on Red Blood Cell (RBC) Transfusion Burden, Iron Chelation Therapy (ICT), and Iron Overload in Adults with Transfusion-Dependent β-Thalassemia (TDT) from the BELIEVE Trial: A Long-Term Analysis

Erythroid Response in Patients with Non-Transfusion-Dependent β-Thalassemia Treated with Luspatercept: Long-Term Data from the BEYOND Trial

Early initiation of disease-modifying therapy can impede or prevent diffuse myocardial fibrosis in sickle cell anemia

A Phase 2a Study Evaluating the Safety and Pharmacokinetics (PK) of Luspatercept in Pediatric Patients with Transfusion-Dependent β-Thalassemia (TDT)

Trial in Progress: A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of the PKR Activator Etavopivat (FT-4202) in Patients with Thalassemia or Sickle Cell Disease

Luspatercept Improves Quality of Life and Reduces Red Blood Cell Transfusion Burden in Patients with Non-Transfusion-Dependent β-Thalassemia in the BEYOND Trial

Loss of Alpha Globin Genes in Human Subjects Is Associated with Improved Nitric Oxide-Mediated Vascular Perfusion

Sustained Reductions in Red Blood Cell (RBC) Transfusion Burden and Events in β-Thalassemia with Luspatercept: Longitudinal Results of the Believe Trial

Longitudinal Effect of Luspatercept Treatment on Iron Overload and Iron Chelation Therapy (ICT) in Adult Patients (Pts) with β-Thalassemia in the Believe Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only